2018 IPO
Allogene Therapeutics Stock
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Sign up today and learn more about Allogene Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Allogene Therapeutics Stock
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment.
Funding History
April 2018 | $412M |
---|---|
September 2018 | $120M |
Management
Chief Executive Officer and Co-Founder
David Chang